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Abstract
It is unknown whether fibrosis-associated microRNAs: miR-21, miR-26, miR-29,
miR-30 and miR-133a are linked to cardiovascular (CV) outcome. The study evalu-
ated the levels of extracellular matrix (ECM) fibrosis and the prevalence of particular
microRNAs in patients with dilated cardiomyopathy (DCM) to investigate any corre-
lation with CV events. Methods: Seventy DCM patients (48  12 years, EF
24.4  7.4%) underwent right ventricular biopsy. The control group was comprised
of 7 patients with CAD who underwent CABG and intraoperative biopsy. Micro-
RNAs were measured in blood and myocardial tissue via qPCR. The end-point was a
combination of CV death and urgent HF hospitalization at the end of 12 months.
There were differential levels of circulating and myocardial miR-26 and miR-29 as
well as myocardial miR-133a when the DCM and CABG groups were compared.
Corresponding circulating and myocardial microRNAs did not correlate with one
another. There was no correlation between microRNA and ECM fibrosis. By the end
of the 12-month period of the study, CV death had occurred in 6 patients, and a
further 19 patients required urgent HF hospitalization. None of the circulating
microRNAs was a predictor of the combined end-point; however, myocardial miR-
133a was an independent predictor in unadjusted models (HR 1.53; 95% CI 1.14-
2.05; P < .004) and adjusted models (HR 1.57; 95% CI 1.14-2.17; P < .005). The
best cut-off value for the miR-133a level for the prediction of the combined end-
point was 0.74 DCq, with an AUC of 0.67. The absence of a correlation between
the corresponding circulating and myocardial microRNAs calls into question their
cellular source. This study sheds new light on the role of microRNAs in ECM fibrosis
in DCM, which warrants further exploration.
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1 | INTRODUCTION
Fibrosis of extracellular matrix (ECM) is a major pathology contribut-
ing to the progression from compensated dilated cardiomyopathy
(DCM) to heart failure (HF).1 Increasing evidence indicates that
microRNAs are important factors in cardiac remodelling, including
ECM fibrosis. Thus far, five microRNAs, namely miR-21, miR-26,
miR-29, miR-30 and miR-133a, have been found to be implicated in
ECM fibrosis, mostly in animal studies.2-4 MicroRNAs function pri-
marily inside cells and tissues, e.g. the myocardium; however, micro-
RNAs have been recently detected in blood samples.5,6 We
examined: (i) the relationship between circulating and myocardial
microRNAs, (ii) the relationship between myocardial microRNAs and
ECM fibrosis, and (iii) the associations between microRNAs and car-
diovascular (CV) outcome.
2 | MATERIALS AND METHODS
2.1 | Study population
Over a period of 14 months, 70 consecutive DCM patients were
enrolled. DCM was diagnosed in line with currently accepted crite-
ria.7,8 The study complies with the World Medical Association Decla-
ration of Helsinki, and the study protocol was approved by the
institutional review board and the ethics committee. All patients
gave written informed consent.
The control group was comprised of 7 patients with CAD who
underwent CABG. During open-heart surgery, transmural needle
biopsies of the anterior LV wall were performed.2
2.2 | Endomyocardial biopsy
Biopsy was performed in accordance with typical guidelines.9 Fibrosis
was determined by a pathologist blinded to the clinical data. Collagen
volume fraction (CVF) was assessed by quantitative morphometry.10
2.3 | Laboratory measurements
RNA was extracted from 100 lL of plasma performed with a mirVana
kit (Life Technologies). Two microlitres of extracted RNA was used to
perform reverse transcription with a TaqMan Advanced MicroRNA
cDNA Synthesis Kit (Life Technologies). qPCR was conducted on 384-
well plates with TaqMan Advanced Master Mix and TaqMan
Advanced Assays targeting: hsa-miR-21-5p, hsa-miR-29b-3p, hsa-miR-
30c-5p, hsa-miR-133a-3p, hsa-mir-26a-5p and hsa-miR-423-3p.11 Fif-
teen microlitre reactions were prepared with pipetting station Bravo
(Agilent Technologies), and a real-time reaction was run and read on
CFX384 Real-Time PCR Detection System (Bio-Rad).
2.4 | Statistical analysis
The combined end-point was composed of CV death and urgent HF
hospitalization by the 12-month point. To examine any correlation
between microRNAs and end-points unadjusted and adjusted for
age, duration of disease, CVF, EF and NT-proBNP, Cox proportional
hazard analyses were performed.
3 | RESULTS
3.1 | Baseline characteristics
At the 12-month follow-up, CV death had occurred in 6 (8.6%) patients
and urgent HF hospitalization had been required for 19 (27.1%)
patients. Thus, the combined end-point occurred in 25 patients (group
1), whereas the remaining 45 patients (group 2) were free from events.
Patients with event-free survival had a significantly shorter duration of
disease (17.8  28.2 vs 36  44.3 months, P < .05) and smaller LV
end-diastolic diameters (33.8  5.4 vs 38.8  8.4 mm/m2; P < .004);
however, LV volumes and EF were similar between the two groups.
Patients from group 2 had less pulmonary hypertension [11 (24.4%) vs
16 (66.7%); P < .001], higher peak oxygen uptake (18.3  6.1 vs
14.5  5.5 mL/kg per min; P < .05) and lower NT-proBNP
(2426.8  4247 vs 5069.7  6852 pg/mL; P < .05).
3.2 | Comparison of microRNAs between DCM and
CABG groups
DCM patients were younger (48.04  12.1 vs 72.5  3.4 years;
P < .05) and had lower EF (24.4  7.4 vs 55.6  3.6%; P < .001).
Both circulating miR-26 (0.47  0.79 vs 0.71  0.75 DCq; P < .05)
and tissue miR-26 (1.4  0.77 vs 1.9  0.12 DCq; P < .05) were
down-regulated in DCM, whereas both circulating miR-29
(7.71  2.78 vs 3.8  1.2 DCq; P < .01) and myocardial miR-29
(1.2  0.9 vs 0.02  0.18 DCq; P < .01) were up-regulated in DCM.
Circulating miR-133a was similar in both groups, but myocardial
miR-133a (0.91  0.97 vs 1.93  0.11 DCq; P < .05) was down-
regulated in DCM.
3.3 | The relationship between the corresponding
circulating and myocardial microRNAs
Only miR-21 was more highly expressed in the myocardium
(1.08  0.97 DCq) compared to blood levels (0.14  0.6 DCq). The
remaining microRNAs were at much higher concentrations in the
bloodstream compared to cardiac tissue: miR-26 (blood:
0.02  0.79 vs myocardium: 1.41  0.77 DCq; P < .001), miR-29
(blood: 2.78  0.78 vs myocardium: 1.22  0.9 DCq; P < .001), miR-
30 (blood: 4.39  1.21 vs myocardium: 0.42  1.43 DCq; P < .001)
and miR-133a (blood: 7.58  2.28 vs myocardium: 0.91  0.97 DCq;
P < .001). None of the corresponding microRNAs correlated with one
another in terms of their blood vs myocardium measurements.
3.4 | MicroRNAs, fibrosis and CV outcome
No correlation was observed between myocardial microRNAs and
fibrosis. There was no difference in any of the circulating microRNAs
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between patients with or without an event. However, tissue miR-
133a was more highly expressed in patients with an event (Table 1).
None of the circulating microRNAs was a predictor of the combined
end-point. Among myocardial microRNAs, myocardial miR-133a was
the only predictor of the end-point in unadjusted (HR 1.53; 95% CI
1.14-2.05; P < .004) and adjusted (HR 1.57; 95% CI 1.14-2.17;
P < .005) models. The best cut-off value for miR-133a level for the
prediction of end-point was 0.73 DCq, with a sensitivity of 58.3%
and specificity of 71.1% (AUC 0.666). Patients with myocardial miR-
133a <0.73 DCq had significantly more CV events (HR 2.49; 95% CI
1.1-5.6; P = .03) than those with miR-133a ≥0.73 DCq (see
Figure 1).
4 | DISCUSSION
The biological role and cellular source of circulating microRNAs are
largely unknown.12 Thus, the issue of whether fibrosis-linked micro-
RNAs are secreted from the cardiac tissue has yet to be resolved. In
this study, corresponding microRNAs in blood and myocardial tissue
were examined simultaneously, and the absence of any correlation
between them was clearly demonstrated.
Preliminary studies showed that ECM fibrosis was associated
with increased expression of pro-fibrotic microRNAs, including miR-
21 and miR-208a and decreased expression of anti-fibrotic micro-
RNAs, including miR-29, miR-30 and miR-133.2-4 In accordance with
these findings, we observed that myocardial miR-29 was up-regu-
lated in our DCM cohort in comparison with CABG patients,
whereas myocardial miR-26 and miR-133a were down-regulated in
DCM. Thus, the aetiology of HF seems to be crucial with respect to
molecular cardiac pathology, including the distribution of microRNAs.
We have previously reported relatively strong correlations between
circulating miR-26 and miR-30 with CVF (r = .48, P < .01 and
r = .72, P < .001, respectively).11 Surprisingly, the corresponding
myocardial microRNAs did not have any relationship with ECM
fibrosis. In a predominantly inflammatory DCM cohort, Besler et al13
found that increased myocardial expression of miR-133 was weakly
associated with fibrosis. The aetiology seems to be of paramount
importance as we did not observe any inflammatory infiltrations on
biopsy, whereas Besler et al studied solely inflammatory DCM.
Bio-SHiFT investigators showed that of 7 circulating microRNAs
previously linked to HF, only miR-22 was associated with the end-
point in a large cohort of unselected HF patients.14 Our study
reveals that circulating microRNAs we selected to examine have no
role in the prognosis in DCM. In a recent study, Besler et al13
reported that myocardial miR-133a expression was related to CV
outcome in inflammatory DCM. Our findings extend this observation
to the non-inflammatory DCM population.
4.1 | Study limitations
The number of patients in the control cohort is small, which was as
a result of a slow recruitment rate. Only selected microRNAs can be
measured with qPCR. Although next-generation sequencing enables
the analysis of virtually all microRNAs, we chose to use qPCR as our
aim was to verify the role of the most “promising” microRNAs in
relation to fibrosis.
5 | CONCLUSIONS
The lack of correlation between corresponding circulating and
myocardial microRNAs calls into question their cellular source. Based
on the expression of a selection of circulating microRNAs (miR-21,
miR-26, miR-29, miR-30 and miR-133a), no prediction can be made
on the expression of their myocardial counterparts. No associations
TABLE 1 Comparison of circulating and myocardial microRNAs
between patients with and without a combined endpoint
Parameter Group 1 (n = 45) Group 2 (n = 25) P-value
mir21 [DCq] 0.08  0.61 0.23  0.57 .33
mir26 [DCq] 0.17  0.8 0.18  0.75 .08
mir29 [DCq] 2.77  0.53 2.8  1.09 .89
mir-30 [DCq] 4.16  1.03 4.57  1.4 .17
mir133a [DCq] 7.6  2.1 7.4  2.7 .69
tissue mir21 [DCq] 1.13  0.96 1.01  0.99 .58
tissue mir26 [DCq] 1.44  0.82 1.34  0.67 .61
tissue mir29 [DCq] 1.31  0.92 1.06  0.85 .29
tissue mir-30 [DCq] 0.36  1.7 0.51  0.66 .33
tissue mir133a [DCq] 0.65  0.75 1.36  1.15 .01
Data are presented as mean  SD.
F IGURE 1 Kaplan–Meier 12-month survival curve for miR-133a
with cut-off value of 0.73 [DCq]. No difference in the combined
end-point was found between the groups stratified by miR-133a
[DCq] value derived from the ROC analysis. The event curves are
initially superimposed but begin to diverge after approximately
200 days
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were found between myocardial microRNAs and fibrosis. Only
myocardial miR-133a was found to be an independent predictor of
prognosis. Although preliminary, this study sheds new light on the
role of microRNAs in DCM pathology and warrants further
exploration.
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